chevron_leftBack
As of 24 April 2025, Royalty Pharma plc has a market cap of $18.27B USD, ranking #1020 globally and #406 in the United States. It ranks #86 in the Healthcare sector, and #12 in the Biotechnology industry.
Key Stats
Market Cap
$18.27BUSD
Enterprise Value
$24.97BUSD
Revenue (TTM)
$2.26BUSD
Net Income (TTM)
$858.98MUSD
Profit Margin
38%
PE Ratio
16.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Pablo Legorreta
open_in_new
Employees
99
Founded
1996
IPO
16 Jun 2020
Website
royaltypharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.6% | -1.6% | -6% | 5.4% | 16% | 14% |
Upcoming Earnings
Earnings Date
Thu, May 8
Earnings Time
sunny
Before Open
EPS Estimate
$1.06
8.2% yoy
Revenue Estimate
$724.69M
28% yoy
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
RPRX
Royalty Pharma PLC Class A
ISIN: GB00BMVP7Y09
Shares Out.:
Shares Outstanding:
433.445M1
Shares Float:
334.381M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
31.69 USD | |
|
RPD
Royalty Pharma PLC Class A
ISIN: GB00BMVP7Y09
|
27.90 EUR | |
|
RPRX
(RPRX/N)
Royalty Pharma PLC Class A
ISIN: GB00BMVP7Y09
|
630.00 MXN |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
